Patients Rally for Access to ALS Treatment NurOwn Amid FDA Petition Efforts
SHERIDAN, WYOMING – July 21, 2025 – In a heartfelt campaign fueled by hope and survival, participants in trials of BrainStorm Cell Therapeutics’ NurOwn have submitted a Citizens’ Petition to the FDA, seeking a renewed evaluation of the stem cell therapy rejected in 2022. Their plea centers on real-world results showing a remarkable 90% survival rate in an expanded access program (EAP) — a figure that many say “defies logic” and demands a second look.
Patients and Families Demand Action
